Welcome to our dedicated page for BridgeBio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BridgeBio Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BridgeBio Pharma's regulatory disclosures and financial reporting.
Viking Global Investors and affiliated entities filed Amendment No. 12 reporting beneficial ownership of 9,792,219 shares of BridgeBio Pharma, Inc. common stock, representing approximately 4.9951% of the outstanding shares. The percentage is rounded to 5% on the cover pages, based on 196,036,786 shares outstanding as of May 31, 2026. The stake is held through a complex Viking Global Opportunities fund structure, with shared voting and dispositive power over all reported shares. As of July 9, 2026, the reporting persons state they ceased to be beneficial owners of more than 5% of BridgeBio’s common stock. Recent trading activity over the prior 60 days is listed in Exhibit 99.14.
Jennifer Cook submitted a Form 144 to sell 148,589 shares of common stock via a stock option exercise on 07/09/2026. The filing lists the sale method as cash through Morgan Stanley Smith Barney LLC. The excerpt also shows prior reported sales in June 2026, including 37,167; 2,196; and 90,240 shares on specified dates.
BridgeBio Pharma entered into a $933.9 million preferred equity financing with funds managed by Sixth Street and HealthCare Royalty. The investors bought 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock at $1,000 per share, with Sixth Street providing $800 million and HealthCare Royalty $133.9 million.
The preferred stock carries a 7% annual cumulative dividend on the accrued amount, payable quarterly in cash or by adding to principal, with step-ups over time up to a 17% cap and additional increases upon certain events. It is initially convertible into common stock at $137.79 per share, with an aggregate initial conversion into 6,777,705 common shares, and ranks senior to common stock for dividends and liquidation. The company may force conversion or redeem the preferred after set anniversaries under specified price and return thresholds, while holders gain voting rights on an as-converted basis and significant protective provisions. BridgeBio also agreed to file a resale shelf registration for the underlying common shares and to seek stockholder approval by June 30, 2027, if required for full conversion.
BridgeBio Pharma, Inc. held its 2026 Annual Meeting of Stockholders on June 22, 2026, where shareholders elected three Class I directors to serve until the 2029 annual meeting. Director Randal W. Scott resigned at the end of his term, and the company stated his resignation was not due to any disagreement.
Stockholders approved, on an advisory basis, the compensation of named executive officers and chose an annual frequency for future say‑on‑pay votes. They also ratified Deloitte & Touche LLP as independent auditor for the year ending December 31, 2026.
Shareholders approved an amendment and restatement of the 2021 Stock Option and Incentive Plan, increasing the shares of common stock reserved for issuance under the plan by 2,000,000 shares.
BridgeBio Pharma director Jennifer E. Cook reported a mix of option exercises, stock grants, and open-market sales of common stock. On June 24, 2026, she sold 37,167 shares at $70.00 and exercised options for 17,167 shares at $16.75 and 20,000 shares at $8.45 per share. Additional sales of 2,196 shares at $68.57 occurred on June 23, 2026. She also received 3,990 restricted stock units and a stock option for 5,277 shares at $68.92 on June 22, 2026. Following these transactions, she directly holds 8,383 shares of common stock. At least one sale was made under a pre-arranged Rule 10b5-1 trading plan, and the new RSUs and options generally vest in full on June 22, 2027, subject to continued board service.
BridgeBio Pharma director Hannah Valantine reported several equity transactions in the company’s stock. She sold 2,808 shares of Common Stock at $68.00 per share and 2,196 shares at $68.57 per share in open‑market sales executed under a pre‑arranged Rule 10b5‑1 sales plan adopted on November 14, 2025.
On the same date, she exercised stock options to acquire 2,808 shares at an exercise price of $41.73 per share and received a grant of 3,990 restricted stock units that will vest in full on June 22, 2027, each representing one share of Common Stock. Following these transactions, she holds 9,259 shares directly and 398 shares indirectly through her spouse.
BridgeBio Pharma director Andrew Lo reported new equity awards. He received 3,990 restricted stock units of Common Stock and now directly holds 18,079 common shares. Separately, he indirectly holds 50,583 common shares jointly with another holder.
Lo was also granted stock options for 5,277 shares of Common Stock at an exercise price of $68.92 per share, expiring on June 21, 2036. Both the RSUs and the stock options vest in full on June 22, 2027, as long as he continues serving on BridgeBio’s board of directors through that date.
BridgeBio Pharma director Charles J. Homcy reported equity awards consisting of restricted stock units and stock options. He received 3,990 RSUs, each representing a contingent right to one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.
The RSUs and the shares underlying the options vest in full on June 22, 2027, conditioned on his continued service on the board of directors through that date. Following the RSU grant, Homcy directly holds 919,876 shares of BridgeBio common stock, plus 5,277 options expiring on June 21, 2036.
BridgeBio Pharma director Eric Aguiar received new equity awards. On June 22, 2026, he was granted 3,990 restricted stock units, each representing one share of common stock, and 5,277 stock options with an exercise price of $68.92 per share.
The RSUs and the shares underlying the stock options vest in full on June 22, 2027, as long as he continues serving on the board through that date. After these awards, he holds 10,579 shares of common stock directly, plus the 5,277 options expiring on June 21, 2036.